Login to Your Account



Horizon Inks $75M AstraZeneca Deal for Genome-Editing Tech

By Nuala Moran
Staff Writer

Wednesday, April 24, 2013
LONDON – Horizon Discovery Ltd. is in line for undisclosed up-front and milestone payments, followed by a potential $75 million from AstraZeneca plc in a deal that signals a move-up for the company, from providing services and products to applying its genome-editing technology in-house to uncover novel targets.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription